As regorafenib potentially inhibits tumor growth through anti‐angiogenesis, several angiokinases such as VEGFR1/2, PDGFR‐β, and FGFR1 are believed to be major targets of regorafenib in cancer treatment (Mross et al., 2012). The gene discussed is FGFR1; the disease is cancer.